Publications 2024

Lauritzen T, Munkhaugen J, Bergan S, Peersen K, Svarstad AC, Andersen AM, Pahnke J, Husebye E, Vethe NT (2024)
The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study
Atheroscler Plus, 55, 31-38
DOI 10.1016/j.athplu.2024.01.001, PubMed 38293288

Pivoriunas J, Vethe NT, Husebye E, Fagerland MW, Bergan S, Kristiansen O, Prof JM, Sverre E (2024)
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Eur Heart J Cardiovasc Pharmacother (in press)
DOI 10.1093/ehjcvp/pvae001, PubMed 38196131

Publications 2023

Lauritzen T, Munkhaugen J, Peersen K, Kristiansen O, Sverre E, Nebauer SD, Villseth M, Andersen AM, Svarstad AC, Jensen EP, Bergan S, Husebye E, Vethe NT (2023)
Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms
Clin Pharmacol Ther, 113 (4), 887-895
DOI 10.1002/cpt.2844, PubMed 36622792

Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman LJ (2023)
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19
Ther Drug Monit, 45 (2), 191-199
DOI 10.1097/FTD.0000000000001014, PubMed 35944126

Sverre E, Munkhaugen J, Kristiansen O, Weedon-Fekjaer H, Peersen K, Gjertsen E, Gullestad L, Bergan S, Husebye E, Vethe NT (2023)
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease
Pharmacol Res Perspect, 11 (3), e01089
DOI 10.1002/prp2.1089, PubMed 37186070

Vethe NT, Åsberg A, Andersen AM, Heier Skauby R, Bergan S, Midtvedt K (2023)
Clinical performance of volumetric finger-prick sampling for the monitoring of tacrolimus, creatinine and haemoglobin in kidney transplant recipients
Br J Clin Pharmacol, 89 (12), 3690-3701
DOI 10.1111/bcp.15870, PubMed 37537150

Publications 2022

Vethe NT, Husebye E, Andersen AM, Bergan S, Kristiansen O, Fagerland MW, Munkhaugen J (2022)
Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma
Ther Drug Monit, 44 (4), 558-567
DOI 10.1097/FTD.0000000000000992, PubMed 35482468

Publications 2021

Andersen AM, Bergan S, Gedde-Dahl T, Buechner J, Vethe NT (2021)
Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients
J Pharm Biomed Anal, 203, 114216
DOI 10.1016/j.jpba.2021.114216, PubMed 34182411

Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S et al. (2021)
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Ther Drug Monit, 43 (2), 150-200
DOI 10.1097/FTD.0000000000000871, PubMed 33711005

Heldal K, Åsberg A, Abedini S, Jenssen TG, Reisæter AV, Bergan S, Hartmann A (2021)
[Estimated glomerular filtration rate as a measurement of kidney function]
Tidsskr Nor Laegeforen, 141 (1)
DOI 10.4045/tidsskr.21.0501, PubMed 35026092

Kindem IA, Bjerre A, Åsberg A, Midtvedt K, Bergan S, Vethe NT (2021)
Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients-A Cross-Validation Study
Ther Drug Monit, 43 (3), 371-375
DOI 10.1097/FTD.0000000000000873, PubMed 33596033

Kristiansen O, Vethe NT, Peersen K, Wang Fagerland M, Sverre E, Prunés Jensen E, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J (2021)
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial
Eur Heart J Cardiovasc Pharmacother, 7 (6), 507-516
DOI 10.1093/ehjcvp/pvaa076, PubMed 32609361

Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H (2021)
In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance
Basic Clin Pharmacol Toxicol, 129 (6), 427-436
DOI 10.1111/bcpt.13645, PubMed 34396687

Skauby RH, Gustavsen MT, Andersen AM, Bjerre A, Åsberg A, Midtvedt K, Vethe NT, Bergan S (2021)
Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients
Ther Drug Monit, 43 (2), 247-255
DOI 10.1097/FTD.0000000000000835, PubMed 33181621

Wong SH, Marquet P, Cattaneo D, Svinarov D, Bergan S, Walson P, Vinks AA, Shipkova M (2021)
Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger
Ther Drug Monit, 43 (6), 719-727
DOI 10.1097/FTD.0000000000000932, PubMed 34654029

Publications 2020

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, Venkataramanan R, Lemaitre F (2020)
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions
Ther Drug Monit, 42 (3), 360-368
DOI 10.1097/FTD.0000000000000761, PubMed 32304488

Gustavsen MT, Midtvedt K, Robertsen I, Woillard JB, Debord J, Klaasen RA, Vethe NT, Bergan S, Åsberg A (2020)
Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
Clin Transl Sci, 13 (6), 1327-1335
DOI 10.1111/cts.12833, PubMed 32652886

Gustavsen MT, Midtvedt K, Vethe NT, Robertsen I, Bergan S, Åsberg A (2020)
Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
Ther Drug Monit, 42 (3), 407-414
DOI 10.1097/FTD.0000000000000697, PubMed 31479042

Klaasen RA, Bergan S, Bremer S, Hole K, Nordahl CB, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2020)
Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
Br J Clin Pharmacol, 86 (6), 1100-1112
DOI 10.1111/bcp.14218, PubMed 31925806

Lemaitre F, Vethe NT, D'Avolio A, Tron C, Robertsen I, De Winter B, Denicolo A, Koch BCP, Venkataramanan R, Van Gelder T, Brunet M, Bergan S, Hesselink DA, Wallemacq P (2020)
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
Ther Drug Monit, 42 (5), 665-670
DOI 10.1097/FTD.0000000000000780, PubMed 32520841

Åsberg A, Bergan S, Bjørkto MH, Mjøen G, Varberg Reisæter A, Robertsen I, Midtvedt K (2020)
Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient-No Intervention Actually Needed
Transplant Direct, 6 (10), e609
DOI 10.1097/TXD.0000000000001058, PubMed 33062842

Publications 2019

Blom KB, Bergo KK, Espe EKS, Rosseland V, Grøtta OJ, Mjøen G, Åsberg A, Bergan S, Sanner H, Bergersen TK, Bjørnerheim R, Skauby M, Seljeflot I, Waldum-Grevbo B, Dahle DO, Sjaastad I, Birkeland JA (2019)
Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: rationale and design of the CENS study
Blood Press, 29 (2), 123-134
DOI 10.1080/08037051.2019.1684817, PubMed 31718316

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O et al. (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther Drug Monit, 41 (3), 261-307
DOI 10.1097/FTD.0000000000000640, PubMed 31045868

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther Drug Monit, 41 (1), 11-18
DOI 10.1097/FTD.0000000000000580, PubMed 30633722

Kristiansen O, Vethe NT, Fagerland MW, Bergan S, Munkhaugen J, Husebye E (2019)
A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
Br J Clin Pharmacol, 85 (12), 2878-2885
DOI 10.1111/bcp.14122, PubMed 31495943

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand Cardiovasc J, 53 (3), 162-168
DOI 10.1080/14017431.2019.1612085, PubMed 31030568

Tuv SS, Nordal K, Vethe NT, Bergan S (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.19.0055, PubMed 31062549

Tuv SS, Vethe NT, Bergan S, Nordal K (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702

Vethe NT, Gustavsen MT, Midtvedt K, Lauritsen ME, Andersen AM, Åsberg A, Bergan S (2019)
Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
Ther Drug Monit, 41 (5), 607-614
DOI 10.1097/FTD.0000000000000655, PubMed 31584926

Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019)
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther Drug Monit, 41 (1), 19-28
DOI 10.1097/FTD.0000000000000578, PubMed 30633723

Åsberg A, Bjerre A, Almaas R, Luis-Lima S, Robertsen I, Salvador CL, Porrini E, Schwartz GJ, Hartmann A, Bergan S (2019)
Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance
Kidney Int Rep, 5 (2), 189-198
DOI 10.1016/j.ekir.2019.11.012, PubMed 32043033

Publications 2018

Egeland EJ, Størset E, Robertsen I, Hermann M, Midtvedt K, Gustavsen MT, Klaasen R, Bergan S, Hartmann A, Åsberg A (2018)
The Authors' Reply
Transplantation, 102 (1), e43-e44
DOI 10.1097/TP.0000000000001961, PubMed 28957846

Eide IA, Reinholt FP, Jenssen T, Hartmann A, Schmidt EB, Åsberg A, Bergan S, Brabrand K, Svensson M (2018)
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
Am J Transplant, 19 (3), 790-800
DOI 10.1111/ajt.15080, PubMed 30125457

Heldal K, Midtvedt K, Hartmann A, Reisaeter AV, Heldal TF, Bergan S, Salvador CL, Åsberg A (2018)
Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study
Transpl Int, 31 (6), 629-638
DOI 10.1111/tri.13137, PubMed 29453878

Klaasen RA, Bergan S, Bremer S, Daleq L, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2018)
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther Drug Monit, 40 (5), 558-566
DOI 10.1097/FTD.0000000000000539, PubMed 30086087

Publications 2017

Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S (2017)
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br J Clin Pharmacol, 83 (11), 2494-2502
DOI 10.1111/bcp.13367, PubMed 28686294

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A (2017)
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), e273-e279
DOI 10.1097/TP.0000000000001796, PubMed 28452920

Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A (2017)
Exposure to Mycophenolate and Fatherhood
Transplantation, 101 (7), e214-e217
DOI 10.1097/TP.0000000000001747, PubMed 28346297

Midtvedt K, Holdaas H, Bergan S, Åsberg A (2017)
Costimulation Blockade: America First, Canada Second … What About Norway?
Am J Transplant, 17 (8), 2230
DOI 10.1111/ajt.14351, PubMed 28508535

Olsen E, Bergan S, Mehl T, Burud I, Ekstrom KE, Di Sabatino M (2017)
Defect related radiative recombination in mono-like crystalline silicon wafers
Phys. Status Solidi A-Appl. Mat., 214 (8), 1700124
DOI 10.1002/pssa.201700124

Salvador CL, Hartmann A, Åsberg A, Bergan S, Rowe AD, Mørkrid L (2017)
Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
Transplant Direct, 3 (12), e332
DOI 10.1097/TXD.0000000000000742, PubMed 29536033

Skauby RH, Bjerre A, Sæves I, Vethe NT, Bremer S, Svarstad A, Bergan S (2017)
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther Drug Monit, 39 (5), 472-482
DOI 10.1097/FTD.0000000000000439, PubMed 28749817

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2017)
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br J Clin Pharmacol, 83 (7), 1457-1465
DOI 10.1111/bcp.13248, PubMed 28146606

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2017)
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'
Br J Clin Pharmacol, 83 (6), 1357-1358
DOI 10.1111/bcp.13276, PubMed 28374426

Publications 2016

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M (2016)
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther Drug Monit, 38 Suppl 1, S1-20
DOI 10.1097/FTD.0000000000000287, PubMed 26977997

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J Diabetes Res, 2016, 4196460
DOI 10.1155/2016/4196460, PubMed 26885529

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V (2016)
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther Drug Monit, 38 Suppl 1, S57-69
DOI 10.1097/FTD.0000000000000255, PubMed 26469711

Størset E, Hole K, Midtvedt K, Bergan S, Molden E, Åsberg A (2016)
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br J Clin Pharmacol, 83 (6), 1350-1352
DOI 10.1111/bcp.13188, PubMed 28008657

Størset E, von Düring ME, Godang K, Bergan S, Midtvedt K, Åsberg A (2016)
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther Drug Monit, 38 (4), 439-46
DOI 10.1097/FTD.0000000000000305, PubMed 27019101

Størset E, Åsberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology (Carlton), 21 (10), 821-7
DOI 10.1111/nep.12738, PubMed 26854648

Publications 2015

Bergan S, Bremer S, Vethe NT (2015)
Drug target molecules to guide immunosuppression
Clin Biochem, 49 (4-5), 411-8
DOI 10.1016/j.clinbiochem.2015.10.001, PubMed 26453533

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S (2015)
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670

Cehajic I, Bergan S, Bjordal K (2015)
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm., 22 (4), 194-197
DOI 10.1136/ejhpharm-2014-000510

de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA (2015)
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
DOI 10.1097/FTD.0000000000000179, PubMed 25551406

Karlsen Bjånes T, Mjåset Hjertø E, Lønne L, Aronsen L, Andsnes Berg J, Bergan S, Otto Berg-Hansen G, Bernard JP, Larsen Burns M, Toralf Fosen J, Frost J, Hilberg T, Krabseth HM, Kvan E, Narum S, Austgulen Westin A (2015)
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin Ther, 38 (1), 222-6
DOI 10.1016/j.clinthera.2015.10.015, PubMed 26546404

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets in vitro
Transpl Int, 28 (10), 1152-61
DOI 10.1111/tri.12617, PubMed 26046470

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382

Salvador CL, Tøndel C, Mørkrid L, Bjerre A, Brun A, Bolann B, Brackman D, Bergan S (2015)
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand J Clin Lab Invest, 75 (8), 710-6
DOI 10.3109/00365513.2015.1091091, PubMed 26426851

Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K (2015)
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study
Transplantation, 99 (10), 2158-66
DOI 10.1097/TP.0000000000000708, PubMed 25886918

Publications 2014

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K, Nordic Society of Paediatric Haematology, Oncology (2014)
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer
Pediatr Blood Cancer, 61 (5), 797-802
DOI 10.1002/pbc.24921, PubMed 24395436

Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H (2014)
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
Eur J Clin Pharmacol, 70 (6), 685-93
DOI 10.1007/s00228-014-1656-3, PubMed 24658827

Størset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, Åsberg A, Midtvedt K, Staatz CE (2014)
Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
Br J Clin Pharmacol, 78 (3), 509-23
DOI 10.1111/bcp.12361, PubMed 25279405

Sæves I, Line PD, Bremer S, Vethe NT, Tveit RG, Meltevik TJ, Bergan S (2014)
Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation
Ther Drug Monit, 36 (1), 46-53
DOI 10.1097/FTD.0b013e31829dcb66, PubMed 24081206

Vethe NT, Ali AM, Reine PA, Andersen AM, Bremer S, Line PD, Rootwelt H, Bergan S (2014)
Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid
Ther Drug Monit, 36 (1), 108-18
DOI 10.1097/FTD.0b013e3182a13900, PubMed 24061448

Publications 2013

Lærum H, Bremer S, Bergan S, Grünfeld T (2013)
A taste of individualized medicine: physicians' reactions to automated genetic interpretations
J Am Med Inform Assoc, 21 (e1), e143-6
DOI 10.1136/amiajnl-2012-001587, PubMed 24001515

Reine PA, Vethe NT, Kongsgaard UE, Andersen AM, Line PD, Ali AM, Bergan S (2013)
Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring
Scand J Clin Lab Invest, 73 (2), 117-24
DOI 10.3109/00365513.2012.745947, PubMed 23281843

Størset E, Holford N, Midtvedt K, Bremer S, Bergan S, Åsberg A (2013)
Importance of hematocrit for a tacrolimus target concentration strategy
Eur J Clin Pharmacol, 70 (1), 65-77
DOI 10.1007/s00228-013-1584-7, PubMed 24071959

Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN (2013)
Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
Transpl Int, 26 (12), 1198-207
DOI 10.1111/tri.12194, PubMed 24118301

Publications 2012

Gjersvik P, Helsing P, Holdaas H, Bergan S (2012)
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]
Tidsskr Nor Laegeforen, 132 (18), 2064-8
DOI 10.4045/tidsskr.12.0389, PubMed 23038197

Sæves I, Line PD, Bergan S (2012)
The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation
Ther Drug Monit, 34 (4), 452-9
DOI 10.1097/FTD.0b013e31825ee3f8, PubMed 22777155

Publications 2011

Midtvedt K, Jenssen T, Hartmann A, Vethe NT, Bergan S, Havnes K, Åsberg A (2011)
No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus
Nephrol Dial Transplant, 26 (11), 3767-72
DOI 10.1093/ndt/gfr153, PubMed 21471328

Sæves I, Vethe NT, Bergan S (2011)
Quantification of 6 glucocorticoids in human plasma by liquid chromatography tandem mass spectrometry: method development, validation, and assessment of matrix effects
Ther Drug Monit, 33 (4), 402-10
DOI 10.1097/FTD.0b013e3182241799, PubMed 21743383

Vethe NT, Midtvedt K, Asberg A, Amundsen R, Bergan S (2011)
[Drug interactions and immunosuppression in organ transplant recipients]
Tidsskr Nor Laegeforen, 131 (20), 2000-3
DOI 10.4045/tidsskr.11.0138, PubMed 22016125

Publications 2010

Vethe NT, Gjerdalen LC, Bergan S (2010)
Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance
Scand J Clin Lab Invest, 70 (8), 583-91
DOI 10.3109/00365513.2010.531141, PubMed 21039189

Publications 2009

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K (2009)
Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
Transplantation, 87 (8), 1221-4
DOI 10.1097/TP.0b013e31819f1001, PubMed 19384170

Bremer S, Vethe NT, Rootwelt H, Jørgensen PF, Stenstrøm J, Holdaas H, Midtvedt K, Bergan S (2009)
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study
J Transl Med, 7, 64
DOI 10.1186/1479-5876-7-64, PubMed 19635156

Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S (2009)
Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study
J Heart Lung Transplant, 28 (9), 919-26
DOI 10.1016/j.healun.2009.05.022, PubMed 19716045

Oiestad EL, Johansen U, Stokke Opdal M, Bergan S, Christophersen AS (2009)
Determination of digoxin and digitoxin in whole blood
J Anal Toxicol, 33 (7), 372-8
DOI 10.1093/jat/33.7.372, PubMed 19796507

Publications 2008

Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, Midtvedt K, Bergan S (2008)
Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Transplantation, 85 (1), 55-61
DOI 10.1097/01.tp.0000296854.68123.03, PubMed 18192912

Bremer S, Vethe NT, Rootwelt H, Bergan S (2008)
Expression of IMPDH1 is regulated in response to mycophenolate concentration
Int Immunopharmacol, 9 (2), 173-80
DOI 10.1016/j.intimp.2008.10.017, PubMed 19010451

Falck P, Asberg A, Byberg KT, Bremer S, Bergan S, Reubsaet JL, Midtvedt K (2008)
Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
Transplantation, 86 (10), 1379-83
DOI 10.1097/TP.0b013e31818aa4b6, PubMed 19034006

Ruud E, Holmstrøm H, Bergan S, Wesenberg F (2008)
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
Pediatr Blood Cancer, 50 (3), 710-3
DOI 10.1002/pbc.21133, PubMed 17226852

Vethe NT, Bremer S, Bergan S (2008)
IMP dehydrogenase basal activity in MOLT-4 human leukaemia cells is altered by mycophenolic acid and 6-thioguanosine
Scand J Clin Lab Invest, 68 (4), 277-85
DOI 10.1080/00365510701724871, PubMed 18609073

Vethe NT, Bremer S, Rootwelt H, Bergan S (2008)
Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals
Ther Drug Monit, 30 (6), 647-55
DOI 10.1097/FTD.0b013e31818955c3, PubMed 18806697

Publications 2007

Bremer S, Rootwelt H, Bergan S (2007)
Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells
Clin Chem, 53 (6), 1023-9
DOI 10.1373/clinchem.2006.081968, PubMed 17463174

Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, Holdaas H (2007)
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
Nephrol Dial Transplant, 23 (3), 1048-53
DOI 10.1093/ndt/gfm632, PubMed 17956893

Publications 2006

Bergan S, Rootwelt H (2006)
[Customized drugs?]
Tidsskr Nor Laegeforen, 126 (18), 2364
PubMed 16998544

Mandla R, Midtvedt K, Line PD, Hartmann A, Bergan S (2006)
Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients
Transpl Int, 19 (1), 44-53
DOI 10.1111/j.1432-2277.2005.00228.x, PubMed 16359376

Oyen O, Strøm EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer P, Brekke IB (2006)
Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome
Am J Transplant, 6 (2), 412-8
DOI 10.1111/j.1600-6143.2005.01184.x, PubMed 16426329

Vethe NT, Bergan S (2006)
Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy
Ther Drug Monit, 28 (5), 608-13
DOI 10.1097/01.ftd.0000245680.38143.ca, PubMed 17038874

Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S (2006)
Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment
Scand J Clin Lab Invest, 66 (1), 31-44
DOI 10.1080/00365510500420259, PubMed 16464785

Publications 2003

Bergan S (2003)
TDM: report concentration, Css, rather than area under the curve, AUC
Ther Drug Monit, 25 (6), 743
DOI 10.1097/00007691-200312000-00015, PubMed 14639063

Mandla R, Line PD, Midtvedt K, Bergan S (2003)
Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients
Ther Drug Monit, 25 (3), 407-14
DOI 10.1097/00007691-200306000-00025, PubMed 12766573

Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T (2003)
C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Transplantation, 76 (8), 1236-8
DOI 10.1097/01.TP.0000085046.39523.D5, PubMed 14578761

Publications 2002

Chikuni O, Nhachi CF, Polder A, Bergan S, Nafstud I, Skaare JU (2002)
Effects of DDT on paracetamol half-life in highly exposed mothers in Zimbabwe
Toxicol Lett, 134 (1-3), 147-53
DOI 10.1016/s0378-4274(02)00184-4, PubMed 12191873

Johansen PW, Bergan S, Rootwelt H, Kvittingen EA, Rugstad HE (2002)
[Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping]
Tidsskr Nor Laegeforen, 122 (29), 2781-3
PubMed 12523145

Molden E, Johansen PW, Bøe GH, Bergan S, Christensen H, Rugstad HE, Rootwelt H, Reubsaet L, Lehne G (2002)
Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
Clin Pharmacol Ther, 72 (3), 333-42
DOI 10.1067/mcp.2002.127396, PubMed 12235455

Publications 2001

Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H (2001)
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
Am J Transplant, 1 (4), 382-6
DOI 10.1034/j.1600-6143.2001.10415.x, PubMed 12099384

Publications 2000

Bergan S, Norge O (2000)
[Better therapeutic potential for azathioprine and mercaptopurine]
Lakartidningen, 97 (16), 1999-2000
PubMed 10826362

Publications 1999

Bergan S, Albrechtsen D, Bentdal O (1999)
[Immunosuppressive agents in organ transplantation]
Tidsskr Nor Laegeforen, 119 (24), 3615-20
PubMed 10563181

Publications 1998

Bergan S (1998)
Azathioprine monitoring in renal transplantation
Department of Clinical Pharmacology, Institute of Clinical Biochemistry, Department of Surgery, University of Oslo, Rikshospitalet, [Oslo], 1 b. (flere pag.)
BIBSYS 982283202, ISBN 82-7633-106-8

Bergan S, Rugstad HE, Bentdal O, Sødal G, Hartmann A, Leivestad T, Stokke O (1998)
Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
Transplantation, 66 (3), 334-9
DOI 10.1097/00007890-199808150-00010, PubMed 9721802

Sagedal S, Asberg A, Hartmann A, Bergan S, Berg KJ (1998)
Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients
Clin Transplant, 12 (6), 553-6
PubMed 9850449

Publications 1997

Bergan S (1997)
Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements
BioDrugs, 8 (6), 446-56
DOI 10.2165/00063030-199708060-00005, PubMed 18031107

Bergan S, Bentdal O, Sødal G, Brun A, Rugstad HE, Stokke O (1997)
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts
Ther Drug Monit, 19 (5), 502-9
DOI 10.1097/00007691-199710000-00003, PubMed 9357091

Bergan S, Rugstad HE, Klemetsdal B, Giverhaug T, Bentdal O, Sødal G, Hartmann A, Aarbakke J, Stokke O (1997)
Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells
Ther Drug Monit, 19 (3), 318-26
DOI 10.1097/00007691-199706000-00013, PubMed 9200774

Giverhaug T, Bergan S, Loennechen T, Rugstad HE, Aarbakke J (1997)
Analysis of methylated 6-mercaptopurine metabolites in human red blood cells: comparison of two methods
Ther Drug Monit, 19 (6), 663-8
DOI 10.1097/00007691-199712000-00010, PubMed 9421108

Publications 1996

Bergan S, Albrechtsen D, Fauchald P (1996)
[Mycophenolate mofetil--a new immunosuppressive agent]
Tidsskr Nor Laegeforen, 116 (20), 2439-41
PubMed 8928103

Publications 1995

Bergan S, Rugstad HE, Bentdal O, Sødal G, Hartmann A, Klemetsdal B, Aarbakke J, Stokke O (1995)
Optimization of azathioprine therapy by measuring 6-thioguanine nucleotides and methylated mercaptopurine in renal allograft recipients
Transplant Proc, 27 (6), 3426
PubMed 8540033

Publications 1994

Bergan S, Rugstad HE, Bentdal O, Endresen L, Stokke O (1994)
Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment
Ther Drug Monit, 16 (1), 13-20
DOI 10.1097/00007691-199402000-00002, PubMed 8160249

Bergan S, Rugstad HE, Bentdal O, Stokke O (1994)
Monitoring of azathioprine treatment by determination of 6-thioguanine nucleotide concentrations in erythrocytes
Transplantation, 58 (7), 803-8
PubMed 7940715

Publications 1993

Bergan S, Rugstad HE, Stokke O, Bentdal O, Frøysaker T, Bergan A (1993)
Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods
Scand J Clin Lab Invest, 53 (5), 471-7
DOI 10.1080/00365519309092542, PubMed 8210969

BRUBAKK O, BERGAN S, PEDERSEN TR, OVERSKEID K (1993)
DIASTOLIC TIME IN PATIENTS TREATED WITH TIMOLOL OR PLACEBO AFTER ACUTE MYOCARDIAL-INFARCTION
Am. J. Noninvas. Cardiol., 7 (4), 220-224
DOI 10.1159/000470283

Publications 1992

Bergan S, Marthinsen FS (1992)
Materialadministrasjon og kapitalrasjonalisering
In Temahefte, ISI, Oslo, 7, 7 s.
BIBSYS 930568982

Publications 1991

Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg KJ (1991)
Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients
Ther Drug Monit, 13 (6), 490-5
DOI 10.1097/00007691-199111000-00004, PubMed 1837629

Publications 1980

Bergan S, Laake K, Bjartveit K (1980)
[Side effects of antitubercular drugs leading to discontinuation of drug therapy]
Tidsskr Nor Laegeforen, 100 (5), 279-82
PubMed 7385151

Publications 1978

Bergan S (1978)
Bivirkninger av tuberkulostatika
S. Bergan, Oslo, 87 s.
BIBSYS 961713232